Biology:β-Lactamase inhibitor

From HandWiki
Short description: Family of enzymes

Clavulanic acid
Sulbactam
Tazobactam
Avibactam
Durlobactam
Relebactam
Vaborbactam

Beta-lactamases are a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. In bacterial resistance to beta-lactam antibiotics, the bacteria have beta-lactamase which degrade the beta-lactam rings, rendering the antibiotic ineffective. However, with beta-lactamase inhibitors, these enzymes on the bacteria are inhibited, thus allowing the antibiotic to take effect. Strategies for combating this form of resistance have included the development of new beta-lactam antibiotics that are more resistant to cleavage and the development of the class of enzyme inhibitors called beta-lactamase inhibitors.[1] Although β-lactamase inhibitors have little antibiotic activity of their own,[2] they prevent bacterial degradation of beta-lactam antibiotics and thus extend the range of bacteria the drugs are effective against.

Medical uses

The most important use of beta-lactamase inhibitors is in the treatment of infections known or believed to be caused by gram-negative bacteria, as beta-lactamase production is an important contributor to beta-lactam resistance in these pathogens. In contrast, most beta-lactam resistance in gram-positive bacteria is due to variations in penicillin-binding proteins that lead to reduced binding to the beta-lactam.[3][4] The gram-positive pathogen Staphylococcus aureus produces beta-lactamases, but beta-lactamase inhibitors play a lesser role in treatment of these infections because the most resistant strains (methicillin-resistant Staphylococcus aureus) also use variant penicillin-binding proteins.[5][6]

Mechanism of action

The Ambler classification system groups known beta-lactamase enzymes into four groups according to sequence homology and presumed phylogenetic relationships. Classes A, C and D cleave beta-lactams by a multi-step mechanism analogous to the mechanism of serine proteases. Upon binding, a serine hydroxyl group in the beta-lactamase active site forms a transient covalent bond to the beta-lactam ring carbonyl group, cleaving the beta-lactam ring in the process. In a second step, nucleophilic attack by a water molecule cleaves the covalent bond between the enzyme and the carbonyl group of the erstwhile beta-lactam. This allows the degraded beta-lactam to diffuse away and frees up the enzyme to process additional beta-lactam molecules.[citation needed]

Currently available beta-lactamase inhibitors are effective against Ambler Class A beta-lactamases (tazobactam, clavulanate, and sulbactam) or against Ambler Class A, C and some Class D beta-lactamases (avibactam). Like beta-lactam antibiotics, they are processed by beta-lactamases to form an initial covalent intermediate. Unlike the case of beta-lactam antibiotics, the inhibitors act as suicide substrates (tazobactam and sulbactam) which ultimately leads to the degradation of the beta-lactamase.[7] Avibactam on the other hand does not contain a beta-lactam ring (non beta-lactam beta-lactamase inhibitor), and instead binds reversibly.[8][9]

Ambler Class B beta-lactamases cleave beta-lactams by a mechanism similar to that of metalloproteases. As no covalent intermediate is formed, the mechanism of action of marketed beta-lactamase inhibitors is not applicable. Thus the spread of bacterial strains expressing metallo beta-lactamases such as the New Delhi metallo-beta-lactamase 1 has engendered considerable concern.[10]

Commonly used agents

Currently marketed β-lactamase inhibitors are not sold as individual drugs. Instead they are co-formulated with a β-lactam antibiotic with a similar serum half-life. This is done not only for dosing convenience, but also to minimize resistance development that might occur as a result of varying exposure to one or the other drug. The main classes of β-lactam antibiotics used to treat gram-negative bacterial infections include (in approximate order of intrinsic resistance to cleavage by β-lactamases) penicillins (especially aminopenicillins and ureidopenicillins), 3rd generation cephalosporins, and carbapenems. Individual β-lactamase variants may target one or many of these drug classes, and only a subset will be inhibited by a given β-lactamase inhibitor.[9] β-lactamase inhibitors expand the useful spectrum of these β-lactam antibiotics by inhibiting the β-lactamase enzymes produced by bacteria to deactivate them.[11]

  • β-lactamase inhibitors with a β-lactam core:
  • β-lactamase inhibitors with a diazabicyclooctane core:
    • Avibactam, approved in combination with ceftazidime (Avycaz, Zavicefta), currently undergoing clinical trials for combination with ceftaroline
    • Durlobactam, approved in combination with sulbactam (Xacduro) to treat hospital‑acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) pneumonia caused by Acinetobacter baumannii-calcoaceticus complex
    • Relebactam, used in combination with imipenem/cilastatin (Recarbrio).[13][14]
  • β-lactamase inhibitors with other types of non β-lactam cores:

Beta-lactamase producing bacteria

Bacteria that can produce beta-lactamases include, but are not limited to:[citation needed]

Research

Some bacteria can produce extended spectrum β-lactamases (ESBLs) making the infection more difficult to treat and conferring additional resistance to penicillins, cephalosporins, and monobactams.[16] Boronic acid derivatives are currently under vast and extensive research as novel active site inhibitors for beta-lactamases because they contain a site that mimics the transition state that beta-lactams go through when undergoing hydrolysis via beta-lactamases. They have been found generally to fit well into the active site of many beta-lactamases and have the convenient property of being unable to be hydrolysed, and therefore rendered useless. This is a favorable drug design over many clinically used competing agents, because most of them, such as clavulanic acid, become hydrolysed, and are therefore only useful for a finite period of time. This generally causes the need for a higher concentration of competitive inhibitor than would be necessary in an unhydrolyzable inhibitor. Different boronic acid derivatives have the potential to be tailored to the many different isoforms of beta-lactamases, and therefore have the potential to reestablish potency of beta-lactam antibiotics.[17]

References

  1. ↑ "The development of beta-lactam antibiotics in response to the evolution of beta-lactamases". Pharmaceutical Research 18 (10): 1391–9. October 2001. doi:10.1023/a:1012272403776. PMID 11697463. 
  2. ↑ "Beta-Lactamase Inhibitors". Department of Nursing of the Fort Hays State University College of Health and Life Sciences. October 2000. http://www.fhsu.edu/nursing/otitis/bl_inhibit.html. 
  3. ↑ "Penicillin-binding proteins and bacterial resistance to beta-lactams". Antimicrobial Agents and Chemotherapy 37 (10): 2045–53. October 1993. doi:10.1128/aac.37.10.2045. PMID 8257121. 
  4. ↑ "Penicillin-binding proteins and beta-lactam resistance". FEMS Microbiology Reviews 32 (2): 361–85. March 2008. doi:10.1111/j.1574-6976.2007.00095.x. PMID 18248419. 
  5. ↑ "Beyond Susceptible and Resistant, Part II: Treatment of Infections Due to Gram-Negative Organisms Producing Extended-Spectrum β-Lactamases". The Journal of Pediatric Pharmacology and Therapeutics 19 (3): 156–64. July 2014. doi:10.5863/1551-6776-19.3.156. PMID 25309145. 
  6. ↑ "Mechanisms of β-lactam resistance among Pseudomonas aeruginosa". Current Pharmaceutical Design 19 (2): 209–22. 2013. doi:10.2174/13816128130203. PMID 22894618. 
  7. ↑ Patrick, Graham L. (2017). An introduction to medicinal chemistry (6th ed.). Oxford, United Kingdom. ISBN 9780198749691. OCLC 987051883. 
  8. ↑ "Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases". Antimicrobial Agents and Chemotherapy 57 (6): 2496–505. June 2013. doi:10.1128/AAC.02247-12. PMID 23439634. 
  9. ↑ 9.0 9.1 "Three decades of beta-lactamase inhibitors". Clinical Microbiology Reviews 23 (1): 160–201. January 2010. doi:10.1128/CMR.00037-09. PMID 20065329. 
  10. ↑ "Dissemination of NDM metallo-β-lactamase genes among clinical isolates of Enterobacteriaceae collected during the SMART global surveillance study from 2008 to 2012". Antimicrobial Agents and Chemotherapy 59 (2): 826–30. February 2015. doi:10.1128/AAC.03938-14. PMID 25403666. 
  11. ↑ "Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy". Clinical Pharmacokinetics 15 (3): 133–64. September 1988. doi:10.2165/00003088-198815030-00001. PMID 3052984. 
  12. ↑ "Tebipenem, a new carbapenem antibiotic, is a slow substrate that inhibits the β-lactamase from Mycobacterium tuberculosis". Biochemistry 53 (22): 3671–8. June 2014. doi:10.1021/bi500339j. PMID 24846409. 
  13. ↑ "FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections". Food and Drug Administration. July 17, 2019. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-complicated-urinary-tract-and-complicated-intra-abdominal-infections. 
  14. ↑ "Cilastatin/imipenem/relebactam — AdisInsight". Springer International Publishing AG. http://adisinsight.springer.com/drugs/800042881. 
  15. ↑ "FDA approves new antibacterial drug" (Press release). Food and Drug Administration. August 29, 2017. Archived from the original on April 23, 2019. Retrieved July 18, 2019.
  16. ↑ "beta-Lactamases in laboratory and clinical resistance". Clinical Microbiology Reviews 8 (4): 557–84. October 1995. doi:10.1128/cmr.8.4.557. PMID 8665470. 
  17. ↑ "Class D β-lactamases: a reappraisal after five decades". Accounts of Chemical Research 46 (11): 2407–15. November 2013. doi:10.1021/ar300327a. PMID 23902256. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Biology:Β-Lactamase_inhibitor&oldid=3615928"